Vertex Pharmaceuticals Awaits FDA Decision on Povetacicept by November 30
Vertex Pharmaceuticals has received FDA acceptance of its biologics license application for povetacicept in IgA nephropathy, with a target action date of November 30, 2026.
Vertex Pharmaceuticals Incorporated has received FDA acceptance of its Biologics License Application for povetacicept, an investigational therapy for immunoglobulin A nephropathy, with the agency assigning a Prescription Drug User Fee Act target action date of November 30, 2026 [2]. The application seeks accelerated approval for treatment of the autoimmune kidney disease.
The povetacicept filing represents Vertex's effort to expand its commercial base beyond the cystic fibrosis franchise that has anchored revenue growth for the past decade [1]. IgA nephropathy affects the kidney's filtration mechanism and currently lacks targeted therapies with durable efficacy, positioning povetacicept as a potential first-in-class option if approved.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.